PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “THIABENDAZOLE”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

HPLC determination and pharmacokinetics of thiabendazole and its major metabolite 5-OH thiabendazole in equine plasma.

Separate high performance liquid chromatographic methods were developed for thiabendazole (TBZ) and 5-hydroxy thiabendazole (5-OH-TBZ) determination in horse plasma using 1-methyl-2-phenyl benzimidazole (MPBZ) as an internal standard. In both methods TBZ and 5-OH-TBZ were extracted from plasma using organic solvents, injected on to a C-18 column, and eluents monitored by a fluorescence detector. However, mobile phase composition, extraction solvent as well as detector wavelength differed in the two methods. The linear range for TBZ was 0.02 to 0.77 microgram ml-1 while that for 5-OH-TBZ was 0.96 to 8.0 micrograms ml-1. A commercially available TBZ oral suspension was administered to four thoroughbred horses in the following manner: days 1 and 2, 44 mg kg-1; days 4 and 5, 440 mg kg-1. Blood samples were collected during the 24 hours after administration and then analysed for TBZ and 5-OH-TBZ. Half-lives (t1/2), maximum plasma concentrations (Cmax), area under plasma concentration time curves (AUC O-alpha), and relative apparent bioavailability (F), were determined using pharmacokinetic equations. The pharmacokinetic parameters varied in the following manner: 1.16 to 13.63 hours (t1/2), 12 to 131 micrograms ml-1 X hours (AUC O-alpha), 3.33 to 8.90 micrograms ml-1 (Cmax), 1.38 to 0.12 (F) after 44 mg kg-1 and 440 mg kg-1 doses, respectively. The ratios of concentrations of TBZ to 5-OH-TBZ after oral administration of TBZ, were significantly lower for 44 mg kg-1 than 440 mg kg-1 doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

New metabolites of thiabendazole and the metabolism of thiabendazole by mouse embryo in vivo and in vitro.

Thiabendazole [2-(4'-thiazolyl)benzimidazole; TBZ], a teratogen in ICR mice, is known to be mainly metabolized to 5-hydroxy-TBZ (5-OH-TBZ) and its conjugates in domestic and laboratory animals. Besides the known metabolites of TBZ, 4-hydroxy-TBZ and 2-acetylbenzimidazole (ABI) were identified as new metabolites of TBZ in the urine of F344 rats and ICR mice. 5-OH-TBZ and ABI, as well as TBZ, were found in the embryos of ICR mice given TBZ orally on day 10 of gestation. In the whole-embryo culture system, 5-OH-TBZ and ABI in the medium, and TBZ, 5-OH-TBZ and ABI in the embryo were detected after 24 hr of culture in 25 or 50 micrograms TBZ ml. However, the amount of metabolites in the embryo in vitro was very small compared with that detected in vivo, whereas the amount of TBZ was comparable. Furthermore, the mouse embryo homogenate, at organogenesis, metabolized TBZ to 5-OH-TBZ or ABI. The specific activity required by this homogenate to form 5-OH-TBZ or ABI was less than 1/1000 of that of the liver microsomal fraction. The results suggested that mouse embryos at organogenesis could metabolize TBZ, although most of the metabolites in the embryo in vivo came from the dam.

Animals↗

Synthesis, antimicrobial activity and chemotherapeutic potential of inorganic derivatives of 2-(4'-thiazolyl)benzimidazole[thiabendazole]: X-ray crystal structures of [Cu(TBZH)2Cl]Cl.H2O.EtOH and TBZH2NO3 (TBZH=thiabendazole).

Thiabendazole (TBZH) reacts with iron(III) nitrate causing protonation of the ligand to yield the nitrate salt [TBZH(2)NO(3)] (1). Reaction of TBZH with copper(II) acetate results in the deprotonation of the ligand yielding [Cu(TBZ)2.(H2O)2] (2). Reactions of TBZH with the chloride, nitrate and butanedioate salts of copper(II) yields [Cu(TBZH)2Cl]Cl.H2O.EtOH (3), [Cu(TBZH)(2)(NO(3))(2)] (4) and [Cu(TBZH)(O(2)C-CH(2)CH(2)-CO(2))] (5), respectively. The TBZH acts as a neutral chelating ligand in 3-5. Molecular structures of 1 and 3 were determined crystallographically. In 1, the asymmetric unit contains one TBZH(2)(+) cation and one NO(3)(-) anion. The structure of 3 comprises a five coordinate copper centre with the metal bound to two chelating TBZH ligands and one chloride. The geometry is best described as trigonal bipyramidal. Hydrogen bonding connects the complex cation with the uncoordinated chloride anion and the water and ethanol solvate molecules. Compound 1 and the copper complexes 2-5, the metal free ligands and a number of simple copper(II) salts were each tested for their ability to inhibit the growth of Candida albicans. The metal free TBZH and its nitrate salt (1) exhibited very poor activity. Complex 2, in which the TBZH is present as an anionic ligand (TBZ(-)), exhibits moderate activity towards the pathogen. Chelation of the neutral TBZH to copper centres (complexes 3-5) results in potent anti-candida activity. The dimethyl sulphoxide (DMSO) soluble complexes 3 and 4, along with metal free TBZH were assessed for their cancer chemotherapeutic potential towards two human epithelial-derived cancer model cell lines. Complexes 3 and 4 displayed similar dose-dependent cytotoxicity in both cell lines with IC(50) values of approximately 50 microM, which were found to be significantly lower than that for metal free TBZH.

Antifungal Agents↗

The inheritance of thiabendazole resistance in Haemonchus contortus.

Haemonchus contortus worm populations isolated from naturally infected sheep at the Pastoral Research Laboratory, Armidale, N.S.W., were found to contain approximately 20% of worms resistant to a 50 mg/kg dose of thiabendazole. Following 3 generations of selection with 50 mg/kg thiabendazole the number of worms removed by the anthelmintic was too small to detect differences between treated and control groups. After more than 15 generations of selection, matings between males from the selected strain and non-resistant females produced resistant males and females in equal numbers. Thus, thiabendazole resistance does not appear to be sex-linked. A dose--response assay on the F2 adults indicated that worms from female resistant x male non-resistant crosses were more resistant than F2 adults of the reciprocal cross. An in vitro technique that identified thiabendazole-resistant eggs by their ability to hatch in a solution containing thiabendazole and 0.1% NaCl solution was also used to study the inheritance of resistance. F1 eggs had similar LC50's to the resistant parents. F2 and back-cross eggs from an original mating of thiabendazole-resistant females x non-resistant males had a higher LC50 than F2 and back-cross eggs from the reciprocal mating, indicating a degree of matroclinous inheritance of resistance. However, the resistant parents had tolerances to thiabendazole exceeding those of F2. F3 eggs had a resistance distribution that ranged from that of the resistant to the non-resistant parent. No significant deviation from linearity was observed in any of the dose--response lines. These results indicate that thiabendazole resistance in H. contortus worms is inherited as an autosomal and semi-dominant trait.

Animals↗

Major involvement of rabbit liver cytochrome P4501A in thiabendazole 5-hydroxylation.

1. Thiabendazole is a widely used food preservative and anthelmintic drug for breeding animal species. In order to characterize precisely the cytochrome P450 isozyme(s) involved in its major route of metabolism, a rapid and sensitive spectrofluorimetric method was developed for the simultaneous determination of thiabendazole and its main hepatic metabolite 5-hydroxythiabendazole. 2. The kinetics of thiabendazole 5-hydroxylation were determined in microsomal preparations from control rabbits or animals previously treated with either beta-naphthoflavone, isosafrole, phenobarbital, rifampicin or clofibrate. These treatments led to specific induction of CYP1A1, 1A2, 2B4, 3A6 and 4A1 respectively. 3. By considering this panel of characterised microsomal preparations, only those obtained from BNF-treated rabbits exhibited an increase in thiabendazole 5-hydroxylase activity Ethoxyresorufin O-deethylation in these microsomes was solely inhibited by thiabendazole. These argue for a specific involvement of the CYP1A subfamily. 4. In the CYP1A subfamily, CYP1A2 appears to be responsible for basal 5-hydroxylation and further unidentified metabolism of thiabendazole in control livers. However, the major involvement of CYP1A1 is supported by the following characteristics of 5-hydroxylation of thiabendazole: (1) the correlation with CYP1A1 expression and (2) the inhibition by ellipticine and not by furafylline, inhibitors of CYP1A1 and CYP1A2 respectively. 5. All these data demonstrated that the rabbit cytochrome P4501A is predominantly involved in thiabendazole 5-hydroxylation which has been suspected to be critical in terms of safety of the parent drug.

Animals↗

Simultaneous determination of thiabendazole and its major metabolite, 5-hydroxythiabendazole, in bovine tissues using gradient liquid chromatography with thermospray and atmospheric pressure chemical ionisation mass spectrometry.

A novel method is presented for the determination of thiabendazole and 5-hydroxythiabendazole in animal tissues. Samples are homogenised in buffer at pH=7.0, extracted with ethyl acetate and cleaned up using CN solid-phase extraction columns. Thiabendazole and 5-hydroxythiabendazole are separated chromatographically using gradient elution and analysed by liquid chromatography-mass spectrometry. Deuterated thiabendazole is employed as an internal standard for thiabendazole determination; 5-hydroxythiabendazole is quantified via external standards. Samples are screened by monitoring the protonated molecular ions at m/z=202 for thiabendazole, 206 for deuterated thiabendazole and 218 for 5-hydroxythiabendazole using thermospray LC-MS. Positives are confirmed by multiple ion monitoring using APCI LC-MS. Validation of the method was carried out at 50, 100 and 200 microg kg(-1). Recoveries for thiabendazole in bovine muscle, liver and kidney ranged from 96-103% with C.V.s between 0.7 and 4.8% and for 5-hydroxythiabendazole recoveries ranged from 70-85% with C.V.s between 3.1 and 11.5%.

Animals↗

The effect of thiabendazole on pain threshold.

Thiabendazole significantly increased the reaction time to thermal stimulus. However, in mice treated with morphine, the reaction time was not in any way different from those treated with combined doses of thiabendazole and morphine. Thiabendazole was found to have an antinociceptive action. The protective dose for 50% of animal (ED50) against p-benzoquinone-induced writhing reflex was found to be 310 mg/kg. The ED50 for aspirin alone was 140 mg/kg. When the ED50 of aspirin was determined in combination with different dose levels of thiabendazole, it showed a marked reduction in the values reaching 50 mg/kg, when 300 mg of thiabendazole was used in combination. Toxicological studies revealed that the oral LD50 for thiabendazole in mice was 2200 mg/kg, and when combined with 140 mg/kg of aspirin, the LD50 was reduced to 900 mg/kg. These findings indicate that thiabendazole possesses an analgesic activity which is potentiated by aspirin, though aspirin was found to significantly enhance its toxicity.

Analgesics↗

Inhibition of thiabendazole metabolism in the rat.

1. A single oral dose of desmethylimipramine (80 mg/kg) administered to rats inhibited the hepatic microsomal hydroxylation of thiabendazole (45%), aniline (30%), biphenyl (30%) and ethylmorphine (15%) in vitro at 5 h after dosage; there was no decrease in cytochrome P-450 or b5. 2. A single oral dose of ethoxyquin (200 mg/kg) to rats inhibited the hepatic microsomal hydroxylation of thiabendazole (65%), aniline (40%) and biphenyl (40%) in vitro at 1 h after dosage; inhibition was less at 5 h. There were no changes in the contents of cytochromes P-450 and b5. 3. The max. plasma concn. of thiabendazole occurred 2--4 h after oral dosing (50--200 mg/kg) to rats. Thiabendazole (100 mg/kg) administered orally 30 min after oral ethoxyquin (400 mg/kg) or thiabendazole (200 mg/kg) administered orally 30 min after oral desmethylimipramine (80 mg/kg) delayed absorption of the thiabendazole and resulted in markedly markedly decreased plasma concentration of the anthelmintic. 4. Simultaneous administration of ethoxyquin (300 mg/kg) potentiated the anthelmintic effect of thiabendazole (750 mg/kg) on the helminth parasite, Nematospiroides dubius, in the mouse. Desmethylimipramine showed no similar potentiation.

Animals↗

Determination of thiabendazole in fruit juices by a new monoclonal enzyme immunoassay.

A competitive, indirect enzyme-linked immunosorbent assay (ELISA) for thiabendazole has been developed and applied to the analysis of fruit juices spiked with this fungicide. The immunoassay is based on a new monoclonal antibody derived from a hapten functionalized at the nitrogen atom in the 1-position of the thiabendazole structure. To our knowledge, such a structure has not been previously used to obtain antibodies to thiabendazole. The I50 value and the detection limit of the ELISA for standards were 0.2 and 0.05 ng/mL, respectively. Fruit juices were analyzed by diluting samples in assay buffer, without extraction or cleanup. Samples were not even centrifuged or filtered to remove fruit pulp. Under these conditions, the immunoassay was able to accurately determine thiabendazole down to 1 ng/mL in orange and grapefruit juices, down to 5 ng/mL in banana juice, and down to 20 ng/mL in apple and pear juices. Sensitivity differences of the ELISA were caused by the minimum dilution required by each juice to minimize matrix effects: 1/10 for orange and grapefruit juices, 1/50 for banana juice, and 1/100 for apple and pear juices. In an attempt to further increase the sensitivity of the immunoassay for matrixes showing the strongest interferences, apple and pear juices spiked with thiabendazole at low levels (1-20 ng/mL) were extracted with ethyl acetate before analysis. This simple procedure entailed a significant reduction of matrix effects, which in fact allowed us to determine accurately as low as 5 ng/mL thiabendazole in apple and pear juices. Irrespective of whether samples were analyzed by the direct dilution method or after extraction, the simplicity, sensitivity, and sample throughput of this monoclonal immunoassay makes it a very convenient method for the routine monitoring of thiabendazole residues in fruit juices.

Antibodies, Monoclonal↗

Attempts to use thiabendazole to improve the immune response in dexamethasone-treated or stressed cattle.

Thiabendazole was evaluated in two separate experiments for its ability to enhance the immune response in dexamethasone-treated or stressed cattle. In the first experiment the cattle received either no drug treatment (controls), dexamethasone intramuscularly (IM), or dexamethasone IM plus thiabendazole orally. All animals were inoculated with heat-killed Brucella abortus strain 19, equine ferritin, tetanus toxoid, and live Corynebacterium equi at the time dexamethasone therapy was initiated. Dexamethasone (0.04 mg/kg/day IM for 3 days) significantly (p less than 0.05) inhibited the lymphocyte blastogenic response to mitogens and the antibody response to ferritin and tetanus toxoid. Thiabendazole given orally (16 mg/kg/day) beginning 24 h prior to antigen and dexamethasone administration and continued for 6 days failed to prevent the dexamethasone-induced suppression of the lymphocyte blastogenic or antibody responses. In the second experiment 51 cattle were divided into a control group and a thiabendazole-treated group. The animals were stressed by weaning, injection of antigen (equine ferritin, tetanus toxoid, B. abortus strain 19 and killed bovine viral diarrhea virus) and castration of the bulls on the day that thiabendazole therapy was started. Thiabendazole administered orally for 5 days at a dosage of 20 mg/kg did not enhance the antibody response to any of the antigens, and was associated with a significantly lower antibody response to B. abortus.

Animals↗

Treatment of Strongyloides stercoralis hyperinfection syndrome with thiabendazole administered per rectum.

There is a rising interest in Strongyloides stercoralis infection due to the expanding population of immunosuppressed patients. Currently the drug of choice for both enteric and tissue forms of infection with this organism is oral thiabendazole. We report a patient with a small bowel obstruction due to S. stercoralis hyperinfection who was unable to take thiabendazole orally. Thiabendazole was administered rectally, and the hyperinfection syndrome resolved. Peak serum concentrations of thiabendazole were achieved 4 hours after rectal administration, and drug levels were sustained longer than previously reported with oral dosing. In addition, elevated levels of thiabendazole metabolites in the patient's urine further confirmed significant absorption. Rectal administration of thiabendazole should be considered for patients unable to take the medication orally.

Administration, Rectal↗

Treatment of pediculosis capitis with thiabendazole: a pilot study.

BACKGROUND: Despite the improvement of health standards, head lice infestation remains a problem worldwide. In addition, there is increasing evidence that head lice are becoming resistant to common pediculocides. AIM: To test the potential effectiveness of thiabendazole, a potent and broad-spectrum antiparasitic and scabicidal agent, for the treatment of pediculosis capitis. METHODS: Twenty-three female patients, aged 7-12 years, who had active head lice infestation, were treated with oral thiabendazole, 20 mg/kg twice daily for 1 day, with repeat treatment after 10 days. RESULTS: On the 11th day, meticulous hair examination showed that 21 patients had responded to treatment [91%; 95% confidence interval (CI), 71-98%], with 14 showing complete responsiveness (61%; 95% CI, 40-78%). The only adverse reactions observed were nausea and mild dizziness, which occurred in four patients, three of whom took the drug on an empty stomach. CONCLUSIONS: Thiabendazole may be a promising treatment for head lice infestation. The primary action of this drug seems to be the inhibition of parasite microtubule polymerization by binding to beta-tubulin. In addition, thiabendazole may interfere with the synaptic transmission of lice through its probable cholinergic effect. As pediculosis capitis is a very communicable disease, the unresponsiveness to thiabendazole could largely be attributed to new infestations during the drug-free interval. Therefore, massive and simultaneous rather than individual and isolated treatments should be used to achieve the epidemiologic control of this ectoparasitosis. As this is a preliminary study, the performance of double-blind, randomized controlled trials on this subject is warranted. Thiabendazole, either alone or in combination with other agents, may prove to be of particular use in areas in which head lice show resistance to common pediculocides.

Administration, Oral↗

Theophylline and antiparasitic drug interactions. A case report and study of the influence of thiabendazole and mebendazole on theophylline pharmacokinetics in adults.

To determine a change in theophylline pharmacokinetics during concomitant thiabendazole or mebendazole therapy, we studied six normal, healthy male volunteers. Aminophylline was administered intravenously, followed by a 30-h blood sampling period. Subjects were randomized to receive thiabendazole or mebendazole, then crossed over to receive the other therapy. Theophylline concentrations were measured utilizing an HPLC technique and a one-compartment model was fit to the data. Theophylline pharmacokinetic parameters were significantly different during thiabendazole therapy. Mean theophylline half-life increased, clearance decreased and elimination rate constant decreased. Two subjects experienced severe nausea and vomiting during thiabendazole therapy. There were no significant differences in theophylline pharmacokinetic parameters during mebendazole therapy. Thiabendazole administration results in a significant decrease in theophylline clearance and beta elimination rate constant. The theophylline half-life increased significantly. Concomitant administration of theophylline and thiabendazole resulted in severe nausea and vomiting. Mebendazole administration did not seem to alter theophylline pharmacokinetics.

Adult↗

[Experimental Studies On The Efficacy Of Thiabendazole Against The Migratory Stages Of Ascarids In Mouse]

INTRODUCTION: It is known that the larvae of ascarids have migrating phase before they reach the intestine. Stewart (1916) reported the pulmonary migration of ascaris larvae in normal host. Beaver et al. (1952) demonstrated the ascaris larvae of animal origin from the biopsied human liver, and applied the term "visceral larva migrans" to the migration of larval nematodes in unsuitable hosts. Either in normal or abnormal host, the migrated larvae cause inflammatory changes in the tissues and produce corresponding symptoms. There have been a considerable number of anthelminthics for the ascaris adult worm, but very few reports concerning the migrating larvae. Smirnov (1932) found no larvicidal effect of santonin and chenopodium oil on the migrating phase. Snyder (1961) also reported that diethylcarbamazine did not relieve the symptoms of visceral larva migrans. Recently, thiabendazole has appeared as a broad spectrum anthelminthic and Brown (1961) reported that the chemical inhibited the development of helminth larvae affecting the migratory phases of roundworms and kidney worms in swine. The present study was designed to confirm the previous reports concerning the anthelminthic effect of thiabendazole and to examine the mechanism of its activity. MATERIALS: Animal: White mice, weighing 18-26 gms, were used regardliss of sex. Parasites: Eggs from the 3cm distal portion of uteri of Toxocara canis and Ascaris lumbricoides were sampled and cultured in 0.5% formalin solution under room temperature for 40-50 days. The embryonated eggs were used for the experiment. Virus: Infuenza A/swine/1957/12 N.I.H., U.S.A. December 20, 1965. Chemical: Thiabendazole; 2-4'-thiazolyle)-benzimidazole, Merck Sharp and Dohme Co. 50% aqueous suspension of the chemical was used for experiment. METHODS: White mice were infected each orally using the stomach tube with 500 eggs of canine-ascaris or 800-1,000 eggs of human ascaris according to the experimental purposes. The viral infection was done by inhalation of 2-3 drops of emulsion containing viurs, and the drug was given by stomach tube. The average dose was 250 mg/kg. Recovery of larvae from the tissues: The larvae in the brain were examined under the microscope by pressing the tissue between two slides. The tissues of liver, lung, and carcasses were macerated with Waring blendor. The macerated tissue was suspended in 20 cc freshly prepared artificial gastric juice (pepsin 1 gm, HCL 0.5 cc, NaCL 0.85 gm, distilled water 100 cc), and incubated over night at 37 degrees C. The sample was centrifuged and the sediments examined for larvae. Inthe first experiment, the fate of the migrating larvae after drug administration was determined in early observation group and late observation group. The early observation group: Three days after the infection of 500 eggs of Toxocara canis, 30 of the mice were diviede into two subgroups; having had a single dose and three doses of drug respectively. Four days after the first dose, the mice were sacrificed and the larvae in tissue were examined. The late observation group: The procedure was the same. The mice were sacrificed 14th day after drug administration. In the second experiment, 30 mice infected with 1,000 eggs of human ascaris each were divided into three groups. One group was control and two groups were group of drug administration. In one group the drug was given two days after the infection and the other in 6 days. Allthe mice were sacrificed on the 8th day after the infection. In the third experiment, 45 mice which were infected with 800 eggs of human ascaris each were divided into three groups. In one group the drug was given 24 hours before the infection and in the other 24 hours after the infection and control A mouse of each group was sacrificed every day for 15 days. In the fourth experiment 100 mice were divided into five groups, I, II, III, IV, V. Group I was infected with influenza virus only, and group II was infeted with 800 eggs of human ascaris only. Group III was infected with the influenza virus 7 days after the ascaris infection. Group IV was treated with a single dose of the drug 24 hours before the infection and the virus was infected 7 days later. Group V was treated with the same dose of drug 24 hours after the infection and virus was infected 7 days later. The fatality of each group was observed every day and also the pathological changes of the lungs in each mouse were examined. RESULT: 1)The number of larvae in the tissues of mice treated with thiabendazole was different according to the observation period and the the number of drug administration. In the early observation group: The number of larvae in the single dose group was 40.9 ± 2.25 (mean ± standard error) The number in organs were 12.8 ± 1.69 in brain, 19.6 ± 1.51 in liver and 8.5 ± 0.88 in muscle. The number in the three doses group was 35.6 ± 1.64. The number in organs were 9.6 ± 0.87 in brain, 16.8 ± 1.75 in liver and 9.2 ± 0.82 in muscle. The average number of larvae from control mice was 85.7 ± 7.45 and the average numbers from different parts of tissue; brain, liver and muscle were 19.7 ± 1.93, 50.8 ± 7.23 and 15.2 ± 1.38 respectively. The average numbers of larvae of single dose group and three dose group were reduced in proportion of 52.2% and 58.5% respectively compared with that of control group. In the late observation group the number of larvae from the single dose group was 28.9 ± 1.35. The numbers in organs were 8.6 ± 0.42 in brain, 10.8 ± 1.13 in liver and 9.5 ± 0.87 in muscle. The number from the three doses group was 26.1 ± 1.01, and the numbers in tissue were 11.3 ± 0.72 in brain, 7.8 ± 0.70 in liver and 19.6 ± 1.45 in muscle. The reduction rates in single dose group and three doses group were 59.3% and 63.2% respectively compared with control group. 2) The numbers of the larvae were examined according to the time of drug administration. Tn the earlier group which were given 3 days after the infection, the numbers of the larvae were 3.5 ± 0.66 in liver and 8.7 ± 0.93 in lungs. But in the later group, the numbers were 7.4 ± 1.04 in liver and 14.4 ± 1.39 in lungs. In the control group, the numbers were 8.7 ± 0.94 in liver and 31.9 ± 1.48 in lungs. The reduction rate of the numbers of larvae from liver and lungs in the early drug administration group were 59.7% and 72.9% respectively. In the delayed drug administrating group, 14.9% and 54.9% were reduced in liver and lungs respectively compared with those of control group. 3) The numbers of the larvae in tissues were different according to the method of drug administration; the groups of durg administration before the infection and after the infection, and control group were 30.6 ± 4.71, 35.9 ± 4.86 and 52.0 ± 6.73 respectively. The numbers of recovered larvae in the mice of drug given before and after infection were reduced to 42.3% and 31.1% as compared with the control group. The peak number of recoverd larvae was observed on the 7th to 8th day in the control group and the group of mice of drug administration before the infection, but on the group of mice of drug administration after the infection was appeared on the 8th to 10th day. The numbers of larvae from liver in the group of mice of drug administration before and after the infection, and control were 16.4 ± 2.93, 19.9 ± 3.16 and 25.8 ± 4.02, respectively. The peak of the number in the liver appeared on the 9th day in the group of drug administration before infection, and in 10th day in the group of drug administration after infection, but in the control group the peak appeared on the 4th day after infection. The numbers of larvae from lungs were 71 ± 1.54, 9.1 ± 1.62 and 12.9 ± 2.42 in the group of before, after and control respectively. The reduction rates were 44.9% and 29.4% as compared with control group. The peak of the number of recovered larvae was shown on the 9th day in the group before infection, in 10th day in the group after infection but in control group the peak appeared on the 8th and 9th day. The larvae in intestinal contents of the group of drug administration before and after infection were reduced 65.6% and 54.7% respectively as compared with control group. 4) The drug also effected the life span of the experimental animals. The group of ascaris infection alone showed the longest period of 13.1 ± 0.90 days. The group was infected by virus alone showed 9.9 ± 0.80 days. The group which was infected by ascaris and virus showed the shortest 3.8 ± 0.40 days. However the groups IV and V which were treated with the drug before and after the infection had almost two times longer longivity than the combined infection group. The pathological findings of the lungs were also different according to the drug administration. The ascaris only group showed the light edematous changes and hemorrhagic spots. The viral group showed severe inflammation and edematous changes on whole lungs and the combined group showed severe inflammation and edema with massive hemorrhage on entire lung field. However the treated group showed much lighter changes than in the group of combined infection. CONCLUSION: The following results were obtained in the present study concerning the effectiveness of thiabendazole upon the larvae of the migrating stages. 1) In the early observation group: The average number of larvae of the group treated with single dose and the group treated with three doses were reduced in proportion of 52.2%, 58.5 % respectively compared with control group. 2) In the late observation group: The reduction rate in the group treated with singel dose and group treated with three doses were 59.3 % and 63.2 % respectively compared with control group. 3) The reduction rates of larvae from liver and lungs in the early drug administration group were 72.9 % and 59.7 % respectively, and 14.9 % and 54.8 % in the delayed drug administration group. 4) In the group of drug given before and after infection, the number of recovered larvae were reduced 42.2 % and 31.1 % respectively compared with the control group. 5) The peak number in organs was delayed 1 to 2 days in the treated group than that of control group. 6) The survival period of the infected mouse was prolonged by the drug administration. 7) The pathological changes were reduced by the administration of the drug. Through above results, it was concluded that thiabendazole reduced the number of migrating larvae and delayed the normal migration of the larvae in tissues and reduced the pathological changes in the tissues.

Journal Article↗